We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sunday newspaper round-up: Restrictions, Unemployment, Blood plasma

Sun, 29th Mar 2020 20:57

(Sharecast News) - "Life in Britain will not return to normal for six months, England's deputy chief medical officer has warned, as ministers begin preparing the public for an extended period of lockdown. At the government's daily press conference, Jenny Harries said that strict social distancing rules may have to be in place for between two and three months. But she added that it would be a further three months before all restrictions were lifted, and even then there were likely to be "bumps" as new clusters of cases of coronavirus were identified." - Sunday Times
Unemployment in Britain is set to more than double in coming months, despite government efforts to incentivise employers to keep staff. Economists warn that the rise in the second quarter of the year will be even sharper than during the financial crisis in 2008. Nomura, the investment bank, predicts an unemployment rate of 8% in the April-June quarter, rising to 8.5% in the following three months, from 3.9% in January, as GDP falls sharply. The 8% rate would be the equivalent of an additional 1.4 million people unemployed and a total jobless level of 2.75 million. - Sunday Times

Rolls-Royce is facing a cash flow crisis as the collapse in air travel caused by coronavirus sees half of its revenues evaporate, leaving the FTSE 100 engineer scrambling for cash. Within days of the scale of the crisis becoming clear, Rolls drew down ?2.5bn of funding to boost its liquidity to ?7bn. However, with the company depending on its civil aerospace business for half of its ?15.4bn underlying revenue, it is likely to need further funding as the coronavirus crisis drags on. - Sunday Telegraph

Doctors have drawn up plans to infuse British coronavirus patients and their carers with blood plasma harvested from "hyperimmune" people who have recovered from the infection in an attempt to save lives. The experimental treatment will be directed at patients who are admitted to hospital with pneumonia caused by the virus in the hope that it reduces the number who end up on ventilators in intensive care units (ICUs). - Guardian

"Italy's political leaders from Left to Right have erupted in fury over the EU's minimalist, insulting, and cack-handed response to the Covid-19 pandemic, warning that lack of economic solidarity risks pushing the bloc's festering divisions beyond the point of no return. "Don't make a tragic mistake. The whole European edifice risks losing its raison d'etre," said the Italian premier, Giuseppe Conte, demanding a giant Marshall Plan funded on the EU's joint credit card to relaunch the productive system once the current nightmare is over." - Sunday Telegraph

Scores of Britain's best-known high street food and drink chains will go bust by the end of April unless banks provide immediate finance, the head of the hospitality industry has warned. Kate Nicholls, chief executive of the UK Hospitality trade body, said further failures are 'inevitable' after 80- strong restaurant chain Chiquitos - owned by The Restaurant Group, whose chief executive is ex-HBOS bank boss Andy Hornby - and the 73-outlet Carluccio's lined up administrators. Nicholls said short-term loans from banks are vital to cover costs pending the arrival of Government grant packages. - UK Daily Mail

Synairgen, listed on the London Stock Exchange and worth just ?50m, is starting a clinical trial in hospitals across the UK with a drug it hopes will prevent coronavirus sufferers from falling seriously ill. [...] Synairgen will now test the treatment on 100 patients with coronavirus. Half will be given its new drug, half will get a placebo. Results could arrive in as soon as eight weeks, which could pave the way for a fast-tracked pivotal study in a bigger group of patients and rapid approval. - Sunday Times

More News
18 Jul 2012 09:39

Synairgen raises 2.5m pounds from placing

Synairgen, a Southampton-based research firm, has placed around 5.56m shares at 45p each, enabling the firm to progress with its primary programme following the successful clinical trial results of an asthma treatment product. The placing has raised £2.5m before expenses. In a related transaction,

Read more
19 Apr 2012 10:22

Synairgen no wheeze as asthma drug trial boosts shares

Southampton based research firm, Synairgen, has rocketed in morning trading after announcing results for a treatment which could protect asthmatics from respiratory virus infections. The drug, called SNG001, stops infections like the common cold spreading to patients' lungs, which is often the caus

Read more
29 Jan 2011 14:04

Takeover targets named

Hold on tight, a wave of patent expiries and generic competition could spark another round of consolidation in the pharma and medical devices sector this year. Billions of dollars have been spent on takeovers or pumped into new issues in recent months as confidence in the recovery grows and cash-ri

Read more
29 Jul 2010 12:51

Small caps round-up: Plantic Technologies, Acal, Anglesey

Shares in Plantic Technologies soared more than 50% after the biodegradeable plastics outfit agreed an 8p per share offer from a company controlled by Gordon Merchant, one of its directors. Acal, which provides technology products and services across Europe and South Africa, said underlying sales

Read more
29 Jul 2010 07:56

Synairgen FY Net Loss GBP2.6M Vs Loss GBP2.5M

LONDON (Dow Jones)--Synairgen PLC (SNG.LN), a respiratory drug discovery and development company with a particular focus on viral defense, Thursday reported a full year net loss of GBP2.6 million, compared with a loss of GBP2.5 million the previous year. MAIN FACTS: -Research and development

Read more
17 May 2010 13:02

Small caps: Cove Energy, Synairgen, Wilmington...

PR specialist Freshwater cut the dividend as profits fell to £32,000 from £106,000 in the six months to end February. Revenues fell to £3.66m from £4.51m. "While the economic environment remains challenging, Freshwater is seeing greater stability and growth potential in most of its markets. Alongsi

Read more
6 May 2010 12:49

Small caps round-up: Griffin Mining, Energy XXI

Griffin Mining posted a rise in profits in the year to December 31 despite a slide in revenues following the collapse in metals prices in late 2008. The company, which operates the Caijiaying zinc-gold mine in China, posted a pre-tax profit of $7.2m, up from $7m in 2008, even as revenues fell to $2

Read more
9 Nov 2009 16:31

London close: Miners power Footsie gains

Mining stocks were at the vanguard of a strong advance from FTSE 100 as commodity prices were boosted by plans outlined by world leaders over the weekend to continue with stimulus measures. Kazakhmys, Fresnillo, Rio Tinto and Vedanta were some of the best performers in the mining sector. Mining g

Read more
9 Nov 2009 14:23

London afternoon: Cadbury rejects Kraft bid

After all the waiting and speculation, the formal bid for Cadbury from US group Kraft Foods proved a disappointment, but it has not dampened sentiment in a buoyant London market. Kraft formally announced a bid for Cadbury on the same terms as the indicative offer announced at the beginning of Septe

Read more
9 Nov 2009 08:42

Synairgen hails swine flu result

The share price of respiratory disease drug developer Synairgen more than doubled in early trading on Monday after positive developments for its inhaled interferon beta programme. Laboratory experiments confirmed the antiviral potency of IFN-beta against 2009 H1N1, better known as ‘swine flu’. The

Read more
27 May 2009 07:59

Small caps round-up: LonZim, Lees Foods, blinkx ...

Zimbabwe-focused investment company LonZim said it is well-placed to benefit from any upturn in the southern African country's economy after investing in several sectors in the six months to February 28. The company posted a pre-tax loss of £911,000 as it invested in telecoms, aviation and hotel se

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.